Necrotizing fasciitis: Difference between revisions

(Move calculators to own section with header (visible in TOC), expanded, before External Links)
(Embed LRINEC Calculator on clinical page)
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Background==
==Background==
*A rapidly progressive infection primarily involving the fascia and subcutaneous tissue
*'''Rapidly progressive, life-threatening infection''' involving fascia and subcutaneous tissue
*Formerly a rare diagnosis, frequency has risen due to an increase in immunocompromised patients with significant risk factors<ref>Hakkarainen TW et al. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg. 2014 Aug. 51 (8):344-72.</ref>
*Mortality: 20-40% even with treatment; increases with delayed diagnosis<ref>Hakkarainen TW et al. Necrotizing soft tissue infections: review and current concepts. ''Curr Probl Surg''. 2014;51(8):344-72. PMID 25069713</ref>
*Gas-formation is NOT a requirement for diagnosis, and radiographical lack of the classically taught gas formation should NEVER rule out necrotizing infection<ref>Misiakos EP et al. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014. 1:36.</ref>
*Early surgical exploration and debridement are the most important prognostic factors
*Most severe form of soft tissue infection and potentially limb and life threatening
*Gas formation is NOT required for diagnosis; absence of gas on imaging does NOT rule out NF<ref>Misiakos EP et al. Current concepts in the management of necrotizing fasciitis. ''Front Surg''. 2014;1:36. PMID 25593960</ref>
*Early recognition and aggressive debridement are major prognostic determinants and delay increases mortality<ref>Wong CH, Khin LW, Heng KS, Tan KC, Low CO (2004). "The LRINEC Laboratory Rother soft tissue infections". Critical Care Medicine 32 (7): 1535–1541. doi:10.1097/01.CCM.0000129486.35458.7D. PMID 15241098</ref>


===Categories===
===Types===
*Type I, polymicrobial
*Type I (Polymicrobial): mixed aerobic/anaerobic organisms; most common overall
*Type II, [[group A streptococcal]]
**Typically in diabetics, immunocompromised, post-surgical patients
*Type III, gas gangrene or [[clostridial]] myonecrosis
**Abdominal wall, perineum ([[Fournier gangrene]])
*Type II (Monomicrobial): Group A Streptococcus (most common) or ''Staphylococcus aureus''
**Can occur in young, healthy patients
**Extremities most common site
*Type III (Gas gangrene): ''Clostridium perfringens'' (myonecrosis)
**Extremely rapid progression; crepitus common
*Type IV: Fungal (immunocompromised, trauma)


===Risk Factors===
===Risk Factors===
*[[DM]]
*[[Diabetes]] (most common comorbidity), IV drug use, obesity
*Drug use
*Immunosuppression ([[HIV]], malignancy, chronic steroids)
*Obesity
*Recent surgery or traumatic wounds
*Immunosuppression
*Peripheral vascular disease, chronic [[renal failure]], [[cirrhosis]]
*Recent surgery
*NSAIDs (may mask early symptoms and promote GAS virulence)
*Traumatic wounds


==Clinical Features==
==Clinical Features==
[[File:NectrotizingFasciitis.jpeg|thumb|Nectrotizing fasciitis]]
*Pain out of proportion to exam (most important early clinical clue)
*Skin exam
**However: some patients present with "la belle indifference" (painless) — ischemic insensate tissue<ref>TheHealthScience. Emergent Management of Necrotizing Soft Tissue Skin Infections. 2013.</ref>
**Erythema (without sharp margins)
*Erythema without sharp margins (unlike [[erysipelas]])
**Exquisitely tender (pain out of proportion to exam)
*Rapidly progressive swelling and induration
***Caveat - some patients present with "la belle indifference"
*Hemorrhagic bullae (violaceous/dusky bullae)
***May be a result of ischemic, insensate tissue<ref>TheHealthScience. Emergent Management of Necrotizing Soft Tissue Skin Infections. Nov 22, 2013. https://thehealthscience.com/topics/emergent-management-necrotizing-soft-tissue-skin-infections.</ref>
*Skin anesthesia (destruction of superficial cutaneous nerves — late but specific)
**Skip lesions
*Crepitus (type I infections; absent in many cases)
**Hemorrhagic bullae (violaceous bullae)
*Skip lesions (areas of normal-appearing skin between involved areas)
***May be preceded by skin anesthesia (destruction of superficial nerves)
*Lymphangitis and lymphadenopathy are ABSENT (fascia lacks lymphatic drainage)<ref>Seal DV. Necrotizing fasciitis. ''Curr Opin Infect Dis''. 2001;14(2):127-32. PMID 11979122</ref>
**Crepitus (in type I infections)
*Systemic toxicity: fever, tachycardia, [[shock]], [[DIC]]
**Lymphangitis and lymphadenopathy are absent in necrotizing fasciitis alone<ref>Seal DV. Necrotizing fasciitis. Curr Opin Infect Dis. 2001;14(2):127–32.</ref><ref>Golger A, Ching S, Goldsmith CH, Pennie RA, Bain JR. Mortality in patients with necrotizing fasciitis. Plast Reconstr Surg. 2007;119(6):1803–7.</ref>
***Lymphangitis is seen in [[cellulitis]]
***Fascia has no lymph drainage
*Swelling/edema may produce compartment syndrome
*Constitutional or toxic shock-like syndrome<ref>Puvanendran R et al. Necrotizing fasciitis. Can Fam Physician. 2009 Oct; 55(10): 981–987.</ref>
**Fever
**Tachycardia
**Systemic toxicity, [[sepsis]]
**[[Conjunctivitis]]


==Differential Diagnosis==
==Differential Diagnosis==
{{SSTI DDX}}
*[[Cellulitis]] (most common misdiagnosis — cellulitis improves with antibiotics; NF does not)
{{Necrotizing Rashes DDX}}
*[[DVT]]
*[[Compartment syndrome]]
*Pyomyositis
*Gas gangrene without fasciitis
*[[Erysipelas]]
 
{{Skin and soft tissue infection DDX}}


==Evaluation==
==Evaluation==
[[File:CTNecrotizingFasciitis.png|thumb|CT of necrotizing fasciitis]]
===Labs===
===Work-Up===
*CBC: leukocytosis (or leukopenia in severe sepsis)
*CBC
*BMP: creatinine (AKI), sodium <135 (associated with NF)
*Chem
*CRP: >150 mg/L
*PT/PTT/INR
*Lactate: elevated (tissue ischemia)
*CK
*CK: may be elevated (myonecrosis)
*Lactate
*Blood cultures, wound cultures
*Coagulation studies (DIC screening)
 
===LRINEC Score<ref>Wong CH, et al. The LRINEC score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. ''Crit Care Med''. 2004;32(7):1535-1541. PMID 15241098</ref>===
*Has NOT been prospectively validated
*Score ≥6: PPV 92% for NF
*10% of patients with score <6 still had NF — low score does NOT rule out NF
*CRP ≥150 (+4), WBC 15-25 (+1) / >25 (+2), Hgb 11-13.5 (+1) / <11 (+2), Na <135 (+2), Cr >1.6 (+2), Glucose >180 (+1)
 
===HUCLA Criteria<ref>Wall DB et al. A simple model to help distinguish NF from non-NF soft tissue infection. ''J Am Coll Surg''. 2000;191(3):227-31. PMID 10989895</ref>===
*WBC >15.4 OR Na <135: associated with NF
*PPV 26%, NPV 99% — useful to rule out NF, not confirm it


===Evaluation===
===Imaging===
*Surgical exploration is the ONLY way to definitively establish the diagnosis of necrotizing infection
*Should NOT delay surgical exploration if clinical suspicion is high
*Imaging
*CT (study of choice if imaging obtained): soft tissue gas, fascial thickening, fluid collections, fat stranding
**Should not delay surgical exploration
*MRI: T2 fascial/subcutaneous edema (very sensitive but time-consuming)
**CT is study of choice - soft tissue gas, edema and fluid collections, fascial thickening with fat stranding
*Bedside US: thickened fascia, subcutaneous fluid, subcutaneous emphysema; limited by gas artifact<ref>Core Ultrasound: Soft Tissue. https://www.coreultrasound.com/sti/</ref>
**US may show thickened fascial planes, fluid between fascial planes, irregularity of the fascia, subcutaneous emphysema. The study may be limited by soft tissue gas. Video lecture<ref>Soft Tissue Ultrasound with Jacob Avila on Core Ultrasound. https://www.coreultrasound.com/sti/</ref>.
*Absence of gas on imaging does NOT exclude NF
**MRI - T2 subcutaneous, intramuscular, and fascial edema
*Absence of gas on imaging '''does not''' exclude diagnosis, as gas may be occult and/or certain organisms do not classically produce gas (i.e. [[Streptococcus|Group A Strep]])
{{LRINEC SCORE}}


===HUCLA NF vs Non-NF Criteria:<ref>Wall DB et al. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg. 2000 Sep;191(3):227-31.</ref>===
===Definitive Diagnosis===
*Retrospective study discovered:
*Surgical exploration is the ONLY way to definitively diagnose NF
**'''WBC count''' '''>15.4'''(x10<sup>3</sup>/mm<sup>3</sup>) OR '''Na''' '''<135'''(mmol/L)
*Findings: grayish necrotic fascia, lack of tissue resistance to blunt dissection, "dishwater" pus, thrombosed vessels
**Associated with NF and combo of both increased likelihood of NF
**PPV 26%/NPV 99%
*Useful tool to rule out NF, not a good tool for confirming presence of NF
**Helps distinguish NF from non-NF infection, when classic 'hard' signs of NF are absent however clinical judgment should still be used in patient with high suspicion of the disease


==Management==
==Management==
*Surgical exploration and debridement is both the definitive diagnostic modality and the definitive treatment
===Surgical===
**Indicated in setting of severe pain, toxicity, fever, elevated CK (with or without radiographic evidence)
*Emergent surgical exploration and debridement — the single most important intervention
*[[Antibiotics]]
*Indicated if: severe pain, systemic toxicity, elevated CK, clinical suspicion with or without imaging findings
**Must cover [[gram positives]], [[gram negatives]], and [[anaerobes]] (especially [[GAS]] and [[clostridium]])
*Repeat debridement (planned "second look") typically at 24-48 hours
**[[Piperacillin-Tazobactam]] 3.375-4.5g q6hr AND [[clindamycin]] 600-900mg q8hr AND [[vancomycin]] 1gm IV q12hr (consider weight base dosing of 20 mg/kg)
*Average: 3-4 debridements before wound management
**[[Piperacillin-Tazobactam]] 3.375-4.5g q6hr and [[linezolid]] 600mg q12hr is an alternative regimen<ref>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2015 May 1;60(9):1448. Dosage error in article text]. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444</ref>
*Delay in surgery increases mortality by approximately 9x
*In diabetics, maintain strict glycemic control (with [[IVFs]] and IV [[insulin]] if necessary)
 
===Antibiotics===
*Must cover '''gram-positives (including MRSA), gram-negatives, AND anaerobes'''
*Empiric regimen:
**Piperacillin-tazobactam 4.5g IV q6h (or meropenem 1g IV q8h)
**+ Vancomycin 25-30 mg/kg IV loading dose (or linezolid 600 mg IV q12h) — MRSA coverage
**+ Clindamycin 900 mg IV q8h — suppresses toxin production (especially GAS exotoxins)<ref>Stevens DL, et al. Practice guidelines for the diagnosis and management of SSTI: 2014 update by IDSA. ''Clin Infect Dis''. 2014;59(2):e10-e52. PMID 24973422</ref>
*Clindamycin should be included in all regimens regardless of other antibiotics
 
===Supportive Care===
*Aggressive IV fluid resuscitation
*Vasopressors for [[septic shock]]
*Serial lactate monitoring
*Blood products for DIC
*ICU admission
 
===IVIG===
*Consider for streptococcal toxic shock syndrome associated with NF (controversial)


==Disposition==
==Disposition==
*Admit to ICU
*ICU admission for all patients
*Surgery consult in ED for any suspected case
*Serial debridements as needed
*Wound management: VAC therapy, skin grafting after infection controlled


== Calculators ==
==Calculators==
{{LRINEC_Calculator}}
{{LRINEC Calculator}}
{{LRINEC Score Calculator}}


==See Also==
==See Also==
*[[Necrotizing soft tissue infections]]
*[[Necrotizing soft tissue infections]]
*[[LRINEC_score|Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) Score]]
*[[Fournier gangrene]]
*[[EBQ:LRINEC Score]]
*[[Cellulitis]]
*[[Gas gangrene]]
*[[Sepsis]]


==References==
==References==
<references/>
<references/>
[[Category:ID]]
*Golger A, et al. Mortality in patients with necrotizing fasciitis. ''Plast Reconstr Surg''. 2007;119(6):1803-7. PMID 17440360
*Puvanendran R et al. Necrotizing fasciitis. ''Can Fam Physician''. 2009;55(10):981-987. PMID 19826154
*Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. ''Clin Infect Dis''. 2007;44(5):705-710. PMID 17278065
 
[[Category:Infectious Disease]]
[[Category:Surgery]]

Latest revision as of 09:55, 22 March 2026

Background

  • Rapidly progressive, life-threatening infection involving fascia and subcutaneous tissue
  • Mortality: 20-40% even with treatment; increases with delayed diagnosis[1]
  • Early surgical exploration and debridement are the most important prognostic factors
  • Gas formation is NOT required for diagnosis; absence of gas on imaging does NOT rule out NF[2]

Types

  • Type I (Polymicrobial): mixed aerobic/anaerobic organisms; most common overall
    • Typically in diabetics, immunocompromised, post-surgical patients
    • Abdominal wall, perineum (Fournier gangrene)
  • Type II (Monomicrobial): Group A Streptococcus (most common) or Staphylococcus aureus
    • Can occur in young, healthy patients
    • Extremities most common site
  • Type III (Gas gangrene): Clostridium perfringens (myonecrosis)
    • Extremely rapid progression; crepitus common
  • Type IV: Fungal (immunocompromised, trauma)

Risk Factors

  • Diabetes (most common comorbidity), IV drug use, obesity
  • Immunosuppression (HIV, malignancy, chronic steroids)
  • Recent surgery or traumatic wounds
  • Peripheral vascular disease, chronic renal failure, cirrhosis
  • NSAIDs (may mask early symptoms and promote GAS virulence)

Clinical Features

  • Pain out of proportion to exam (most important early clinical clue)
    • However: some patients present with "la belle indifference" (painless) — ischemic insensate tissue[3]
  • Erythema without sharp margins (unlike erysipelas)
  • Rapidly progressive swelling and induration
  • Hemorrhagic bullae (violaceous/dusky bullae)
  • Skin anesthesia (destruction of superficial cutaneous nerves — late but specific)
  • Crepitus (type I infections; absent in many cases)
  • Skip lesions (areas of normal-appearing skin between involved areas)
  • Lymphangitis and lymphadenopathy are ABSENT (fascia lacks lymphatic drainage)[4]
  • Systemic toxicity: fever, tachycardia, shock, DIC

Differential Diagnosis

Template:Skin and soft tissue infection DDX

Evaluation

Labs

  • CBC: leukocytosis (or leukopenia in severe sepsis)
  • BMP: creatinine (AKI), sodium <135 (associated with NF)
  • CRP: >150 mg/L
  • Lactate: elevated (tissue ischemia)
  • CK: may be elevated (myonecrosis)
  • Blood cultures, wound cultures
  • Coagulation studies (DIC screening)

LRINEC Score[5]

  • Has NOT been prospectively validated
  • Score ≥6: PPV 92% for NF
  • 10% of patients with score <6 still had NF — low score does NOT rule out NF
  • CRP ≥150 (+4), WBC 15-25 (+1) / >25 (+2), Hgb 11-13.5 (+1) / <11 (+2), Na <135 (+2), Cr >1.6 (+2), Glucose >180 (+1)

HUCLA Criteria[6]

  • WBC >15.4 OR Na <135: associated with NF
  • PPV 26%, NPV 99% — useful to rule out NF, not confirm it

Imaging

  • Should NOT delay surgical exploration if clinical suspicion is high
  • CT (study of choice if imaging obtained): soft tissue gas, fascial thickening, fluid collections, fat stranding
  • MRI: T2 fascial/subcutaneous edema (very sensitive but time-consuming)
  • Bedside US: thickened fascia, subcutaneous fluid, subcutaneous emphysema; limited by gas artifact[7]
  • Absence of gas on imaging does NOT exclude NF

Definitive Diagnosis

  • Surgical exploration is the ONLY way to definitively diagnose NF
  • Findings: grayish necrotic fascia, lack of tissue resistance to blunt dissection, "dishwater" pus, thrombosed vessels

Management

Surgical

  • Emergent surgical exploration and debridement — the single most important intervention
  • Indicated if: severe pain, systemic toxicity, elevated CK, clinical suspicion with or without imaging findings
  • Repeat debridement (planned "second look") typically at 24-48 hours
  • Average: 3-4 debridements before wound management
  • Delay in surgery increases mortality by approximately 9x

Antibiotics

  • Must cover gram-positives (including MRSA), gram-negatives, AND anaerobes
  • Empiric regimen:
    • Piperacillin-tazobactam 4.5g IV q6h (or meropenem 1g IV q8h)
    • + Vancomycin 25-30 mg/kg IV loading dose (or linezolid 600 mg IV q12h) — MRSA coverage
    • + Clindamycin 900 mg IV q8h — suppresses toxin production (especially GAS exotoxins)[8]
  • Clindamycin should be included in all regimens regardless of other antibiotics

Supportive Care

  • Aggressive IV fluid resuscitation
  • Vasopressors for septic shock
  • Serial lactate monitoring
  • Blood products for DIC
  • ICU admission

IVIG

  • Consider for streptococcal toxic shock syndrome associated with NF (controversial)

Disposition

  • ICU admission for all patients
  • Surgery consult in ED for any suspected case
  • Serial debridements as needed
  • Wound management: VAC therapy, skin grafting after infection controlled

Calculators

LRINEC Score

LRINEC Score — Necrotizing Soft Tissue Infection
Lab Value Select
CRP (mg/L) 1 <150 (0)   ≥150 (+4)
WBC (×10³/μL) 1 <15 (0)   15–25 (+1)   >25 (+2)
Hemoglobin (g/dL) 1 >13.5 (0)   11–13.5 (+1)   <11 (+2)
Sodium (mEq/L) 1 ≥135 (0)   <135 (+2)
Creatinine (mg/dL) 1 ≤1.6 (0)   >1.6 (+2)
Glucose (mg/dL) 1 ≤180 (0)   >180 (+1)
LRINEC Score / 13
Interpretation
<6 Low risk — <50% probability of necrotizing fasciitis. Consider other diagnoses but maintain clinical suspicion.
6–7 Moderate risk — 50–75% probability. Consider surgical consultation and advanced imaging.
≥8 High risk — >75% probability of necrotizing fasciitis. Urgent surgical consultation for exploration.
References
  • Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535-1541. PMID 15241098.
  • Caution: LRINEC has limited sensitivity (~80%). A low score does NOT rule out necrotizing fasciitis. Clinical suspicion should always guide management.

Template:LRINEC Score Calculator

See Also

References

  1. ↑ Hakkarainen TW et al. Necrotizing soft tissue infections: review and current concepts. Curr Probl Surg. 2014;51(8):344-72. PMID 25069713
  2. ↑ Misiakos EP et al. Current concepts in the management of necrotizing fasciitis. Front Surg. 2014;1:36. PMID 25593960
  3. ↑ TheHealthScience. Emergent Management of Necrotizing Soft Tissue Skin Infections. 2013.
  4. ↑ Seal DV. Necrotizing fasciitis. Curr Opin Infect Dis. 2001;14(2):127-32. PMID 11979122
  5. ↑ Wong CH, et al. The LRINEC score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535-1541. PMID 15241098
  6. ↑ Wall DB et al. A simple model to help distinguish NF from non-NF soft tissue infection. J Am Coll Surg. 2000;191(3):227-31. PMID 10989895
  7. ↑ Core Ultrasound: Soft Tissue. https://www.coreultrasound.com/sti/
  8. ↑ Stevens DL, et al. Practice guidelines for the diagnosis and management of SSTI: 2014 update by IDSA. Clin Infect Dis. 2014;59(2):e10-e52. PMID 24973422
  • Golger A, et al. Mortality in patients with necrotizing fasciitis. Plast Reconstr Surg. 2007;119(6):1803-7. PMID 17440360
  • Puvanendran R et al. Necrotizing fasciitis. Can Fam Physician. 2009;55(10):981-987. PMID 19826154
  • Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44(5):705-710. PMID 17278065
Retrieved from "https://www.wikem.org/w/index.php?title=Necrotizing_fasciitis&oldid=389545"